Is there a difference between IL-17i and TNFi in preventing radiographic progression in radiographic axSpA? Head to head study secukinumab vs. adalimumab biosimilar shows no sig difference with low radiographic progression. #ACRBest Abs#L15 @RheumNow #ACR22 https://t.co/UiHMtakaPz